MRTX-500: Phase II trial of sitravatinib (sitra) plus nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy

被引：12

作者：

Leal, T. A. ^{[1
]}

Berz, D. ^{[2
]}

Rybkin, I. ^{[3
]}

Iams, W. T. ^{[4
]}

Bruno, D. ^{[5
]}

Blakely, C. ^{[6
]}

Spira, A. ^{[7
]}

Patel, M. ^{[8
]}

Waterhouse, D. M. ^{[9
]}

Richards, D. ^{[10
]}

Pham, A. ^{[11
]}

Jotte, R. ^{[12
]}

Garon, E. B. ^{[13
]}

Hong, D. S. ^{[14
]}

Shazer, R. ^{[15
]}

Yan, X. ^{[16
]}

Latven, L. ^{[17
]}

He, K. ^{[18
]}

机构：

[1] Emory Univ, Hematol Oncol, Atlanta, GA 30322 USA

[2] Beverly Hills Canc Ctr, Cellular Therapeut, Beverly Hills, CA USA

[3] Henry Ford Canc Inst, Hematol Oncol, Detroit, MI USA

[4] Vanderbilt Ingram, Hematol Oncol, Nashville, TN USA

[5] Univ Hosp, Seidman Canc Ctr, Hematol Oncol, Cleveland, OH USA

[6] Univ Calif San Francisco, Med, San Francisco, CA 94143 USA

[7] Virginia Canc Specialist, Res Inst, Fairfax, VA USA

[8] Univ Minnesota, Masonic Canc Ctr, Hematol Oncol & Transplantat, Minneapolis, MN USA

[9] OHC, Hematol Oncol, Cincinnati, OH USA

[10] Texas Oncol, Hematol Oncol, Tyler, TX USA

[11] Northwest Canc Specialists, Oncol, Portland, OR USA

[12] Rocky Mt Canc Ctr, US Oncol Res, Oncol, Denver, CO USA

[13] UCLA Hematol Oncol Santa Mon, Div Heme Onc, Med, Santa Monica, CA USA

[14] Univ Texas MD Anderson Canc Ctr, Oncol, Houston, TX 77030 USA

[15] TRACON Pharmaceut, Oncol, San Diego, CA USA

[16] Mirati Therapeut, Clin Discovery, San Diego, CA USA

[17] Mirati Therapeut, Financial Interests, San Diego, CA USA

[18] Ohio State Univ, Ctr Comprehens Canc, Oncol, Columbus, OH 43210 USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.01.052

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

43P

引用

页码：S19 / S20

页数：2